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Aim: To assess the frequency and spectrum of chromosome aberrations and micronuclei in peripheral blood lymphocytes of patients 
with parotid salivary gland tumors and relapse of breast cancer during the course of neutron therapy. Materials and Methods: Samples 
of peripheral blood were obtained from 9 patients with parotid salivary gland tumors (T3N0–3M0) and 8 patients with relapse of breast 
cancer before, after first fraction and at the end of neutron therapy. The treatment course specified 5.5–8.4 Gy (equivalent to 23–
44 Gy of photon irradiation) with 1.3–2.2 Gy per fraction for patients with parotid salivary gland tumors and 4,8–8.0 Gy (equivalent 
to 30–40 Gy of photon irradiation) with 1.6 Gy per fraction for patients with relapse of breast cancer. Control group established for 
conventional cytogenetic analysis consisted of 15 healthy persons. Assessment of chromosome aberrations frequency was performed 
on routinely stained metaphase plates. Lymphocytes from the same patients were analyzed by micronucleus test in combination with 
fluorescent in situ hybridization (FISH) using pancentromeric DNA probe. Results: Level of chromosome aberrations and micronuclei 
significantly increased in lymphocytes of patients from both groups during neutron therapy (P < 0.05). This increase was mainly due 
to chromosome-type aberrations and centromere-negative micronuclei. The prevalent types of aberrations are in agreement with 
theoretical mechanisms of neutron effects on cells. Conclusion: Cytogenetic effects of fast neutron therapy in lymphocytes of patients 
with parotid salivary gland tumors and relapse of breast cancer were observed. A positive dynamics of radiation-induced chromo-
somal damages formation during the course was denoted in lymphocytes of cancer patients in both groups.
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World-wide experience of past decades showed 
that neutron therapy significantly increases the treat-
ment efficacy of patients with radioresistant head and 
neck cancer and breast cancer due to higher damaging 
effects of neutrons [1]. However, it is often hard to elimi-
nate the most radioresistant fraction of tumor cells 
without crossing the border of healthy tissue tolerance 
[2–4]. This may result in late adverse reactions to neu-
tron therapy and thus, require the development of new 
effective approaches to assess the radiation damage 
in healthy tissues of patient during neutron therapy.
Cytogenetic assessment is recommended by World 
Health Organization, United Nations Scientific Com-
mittee on the Effects of Atomic Radiation and Interna-
tional Atomic Energy Agency as accurate and reliable 
assay to indicate the radiation damage in human cells 
[5]. Biological effects of ionizing radiation are the sum 
of absorbed dose, dose distribution throughout the 
body and individual radiosensitivity of the patient [6]. 
In addition, the issue of radiation-induced numeri-
cal chromosome aberrations in human cells remains 
open today [8]. Data concerning the aneugenic effect 
of radiation are insufficient and sometimes contra-
dictory to make a clear conclusion. This requires the 
assessment of both structural and numerical chro-
mosome abnormalities for complete characterization 
of radiation-induced effects in cells of cancer patients 
during the neutron therapy. In addition to conven-
tional cytogenetic analysis of routinely stained meta-
phase plates cytokinesis-blocked micronucleus test 
in combination with fluorescent in situ hybridization 
(FISH) is used to assess the levels of both structural 
and numerical chromosomal abnormalities in human 
peripheral blood lymphocytes [9, 10]. Thus, the aim 
of this study was to analyze the level and spectrum 
of chromosomal aberrations and micronuclei in pe-
ripheral blood lymphocytes of patients with parotid 
salivary gland tumors and relapse of breast cancer 
during the neutron therapy.
MATERIALS AND METHODS
Patients. Samples of peripheral blood were 
obtained from 9 patients with parotid salivary gland 
tumors (T3N0–3M0) and 8 patients with relapse 
of breast cancer before, 24 h after first fraction and 
at the end of neutron therapy. Before entering the 
study all subjects were informed about the aim and the 
experimental details and gave their signed informed 
consent. This study was approved by Bioethics Com-
mittee of Cancer Research Institute Siberian Branch 
of the Russian Academy of Medical Sciences. 
Therapy using 6.3 MeV fast neutrons was per-
formed on cyclotron U-120 at the Research Institute 
of Nuclear Physics of Tomsk Polytechnic University. 
The treatment course specified 5.5–8.4 Gy (equivalent 
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to 23–44 Gy of photon irradiation) with 1.3–2.2 Gy per 
fraction for patients with parotid salivary gland tumors 
and 4.8–8.0 Gy (equivalent to 30–40 Gy of photon 
irradiation) with 1.6 Gy per fraction for patients with 
relapse of breast cancer. Two radiation field sizes were 
used: 6 by 6 cm and 6 by 8 cm. 
Control group. Control group established for con-
ventional cytogenetic analysis consisted of 15 healthy 
persons. 
Blood sampling. Samples of venous blood 
(4 mL per each sampling time) were collected 
in heparinized vacutainer tubes (Greiner, Austria). 
Patients were sampled three times throughout the 
study. Using blood samples collected before therapy, 
individual baseline values for each test parameter 
were done. The pre-treatment blood sample was col-
lected two hours prior to the first fraction of radiation. 
The response of peripheral blood leukocytes to the 
radiotherapy was evaluated on blood samples taken 
after the application of the first dose, as well as after 
the last received radiotherapy dose.
After venipuncture, the blood samples were coded 
and transferred to laboratory. They were processed 
immediately after transportation and cell cultures were 
launched for the analysis of structural chromosomal 
aberrations and the cytokinesis-block micronucleus 
(CBMN) assay in combination with FISH following the 
recommendations by International Atomic Energy 
Agency and the HUMN project [11–13]. 
Chromosomal aberrations analysis. Chromo-
somal aberrations analysis was performed according 
to International Atomic Energy Agency guidelines 
[12]. In brief, cultures were incubated in vitro for 
52 h in RPMI-1640 medium (Sigma, USA) with 10% 
fetal bovine serum (Thermo Scientific, USA) and 
stimulated by phytohaemagglutinin (PHA; PanEco 
Russia). To arrest dividing lymphocytes in metaphase, 
colchicine was added 2 h prior to the harvest. Prepara-
tions were made according to the standard procedure. 
Slides were stained with 5% Giemsa solution (Sigma, 
USA). All slides were coded and scored blindly at 1000´ 
magnification under oil immersion on microscope 
“Axioskop” (Carl Zeiss, Germany). Structural chromo-
somal aberrations were classified based on the num-
ber of sister chromatids and breakage events involved. 
Only metaphases containing 45–47 centromeres were 
analyzed. Three hundred metaphases per sample per 
each point of irradiation were analyzed.
CBMN assay in combination with FISH. CBMN 
assay was performed using lymphocyte cultures 
according to the standard protocol with minor modi-
fications [13]. Lymphocyte cultures were incubated 
in RPMI-1640 medium for 72 h. Cytochalasin B was 
added at 44 h in final concentration 5 µg/mL. Slides 
were made according to the standard procedure. 
FISH was performed with the use of pancentro-
meric DNA probe specific for the pericentromeric sat-
ellite DNA sequences of all human chromosomes [7]. 
A fluorescent label (TAMRA-dUTP) was incorporated 
into the DNA probes using the standard nick-transla-
tion reaction [14]. The specificity of the resultant DNA 
probes was estimated in normal human metaphase 
plates. FISH was performed as described earlier [15].
Criteria proposed by M. Fenech et al. (2007) 
for MN identification were used [11]. Altogether 
1000 binuclear (BN) cells per each sample per point 
of experiment were scored. Total number of MN and 
their types were determined, along with the number 
of micronucleated cells.
The nonparametric Wilcoxon matched pairs test 
was used to statistically estimate the differences 
of chromosomal aberrations and micronuclei levels 
between various time points during radiation therapy.
RESULTS AND DISCUSSION
Frequency of aberrant metaphases before radia-
tion therapy was 0.32 ± 0.05% in the group of patients 
with parotid salivary gland tumors and 1.62 ± 0.72% 
in the group of patients with relapse of breast cancer. 
No significant differences were observed in the mean 
frequency of aberrant metaphases between patients 
with parotid salivary gland tumors and healthy per-
sons (0.29 ± 0.14%, P = 0.69). However, significant 
differences were found between patients with relapse 
of breast cancer and control group (P = 0.012).
Frequency of micronuclei in groups of patients with 
parotid salivary gland tumors (0.72 ± 0.05%) and with 
relapse of breast cancer (1.12 ± 0.19%) was signifi-
cantly higher than in healthy persons (0.55 ± 0.04%, 
P < 0.05) [9].
Frequency of all chromosomal aberrations in-
creased in the group of patients with relapse of breast 
cancer from 2.01 ± 0.95% before the radiation 
therapy to 3.13 ± 0.84% after the first irradiation and 
to 4.65±0.91% at the end of treatment course (Ta-
ble 1). Significant increasing was observed also for the 
frequencies of aberrant metaphases (P = 0.046), chro-
mosome-type aberrations (P = 0.017), atypical mono-
centrics (P = 0.027), paired fragments (P = 0.010), 
centromere-negative micronuclei (P = 0.016) and sum 
of all micronuclei (P = 0.01) only at the end of radiation 
therapy in comparison with levels before the treatment.
In the group of patients with parotid salivary gland 
tumors the frequency of all chromosomal aberra-
tions was significantly higher after the first fraction 
(2.00 ± 0.31%) and at the end of neutron therapy 
(3.01 ± 0.35%) in comparison with 0.32±0.15% before 
the treatment (P < 0.05, Table 2). Opposite to the pa-
tients with relapse of breast cancer the frequency of all 
chromosomal aberrations and micronuclei significantly 
increased after the first fraction of the therapy and sub-
sequently till to the end of treatment course (Table 2).
Chromosome-type aberrations in peripheral blood 
lymphocytes are known to be a specific biomarker 
of ionizing radiation exposure [16–18]. As expected, 
in our study chromosome-type aberrations prevailed 
among detected abnormalities at the end of the neu-
tron therapy (97 and 95.5% in the groups of patients 
with salivary gland tumors and with relapse of breast 
cancer, respectively). In turn, the most frequent ab-
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normalities among the chromosome-type aberrations 
were paired fragments. This is not surprising because 
of paired fragments formed both due to the lack of DNA 
double-strand break repair and as a result of misrepair 
together with chromosome translocations. More-
over, most of detected micronuclei did not contain 
centromere (centromere-negative micronuclei) and 
corresponded to acentric chromosomal fragments.
Table 1. Frequencies of chromosomal aberrations and micronuclei in pe-
ripheral blood lymphocytes of 8 patients with relapse of breast cancer dur-
ing neutron therapy (mean  ± standard error, %) 
Time point Before treat-ment
After the 1st 
fraction
At the end 
of treatment
Dose range of neutron irradiation - 1.6 Gy 4.8–6.56 Gy
Equivalent dose range 25–35 Gy
Chromosome aberration analysis (routinely stained metaphase plates)
Number of analyzed metaphase 
plates 
2260 2440 2290
Aberrant metaphases 1.62 ± 0.72 2.68 ± 0.78 4.16 ± 0.77*
Total number of aberrations 2.01 ± 0.95 3.13 ± 0.84 4.65 ± 0.91
Chromosome-type aberrations 1.81 ± 0.86 3.03 ± 0.74 4.45 ± 0.75*
Paired fragments 1.01 ± 0.41 1.62 ± 0.43 2.74 ± 0.38*
Ring chromosomes 0.16 ± 0.12 0.25 ± 0.13 0.20 ± 0.08
Dicentric chromosomes 0.37 ± 0.22 0.45 ± 0.21 0.54 ± 0.26
Atypical monocentrics 0.08 ± 0.05 0.33 ± 0.14 0.75 ± 0.21*
Double-minute chromosomes 0.16 ± 0.11 0.37 ± 0.13 0.20 ± 0.14
Chromatid-type aberrations 0.21 ± 0.08 0.09 ± 0.09 0.21 ± 0.16
Chromatid breaks 0.16 ± 0.09 0.05 ± 0.05 0.21 ± 0.16
Isochromatid breaks 0.04 ± 0.04 0.04 ± 0.04 0
Micronucleus test (using pancentromeric DNA-probe)
Total number of micronuclei 1.24 ± 0.19 1.83 ± 0.06 3.48 ± 1.01*
Centromere-negative micronuclei 0.78 ± 0.16 1.44 ± 0.08 2.60 ± 0.88*
Centromere-positive micronuclei 0.46 ± 0.06 0.39 ± 0.08 0.88 ± 0.14
Nucleoplasmatic bridges 0.02 ± 0.01 0.04 ± 0.01 0.09 ± 0.03
Notes: *statistically significant differences in comparison with level before 
treatment, P < 0.05
Table 2. Frequencies of chromosomal aberrations and micronuclei in pe-
ripheral blood lymphocytes of 9 patients with parotid salivary gland tumors 
during neutron therapy (mean  ± standard error, %)
Time point Before treat-ment
After the 1st 
fraction
At the end 
of treatment
Dose range of neutron irradiation - 1.3–2.2 Gy 5.5–8.4 Gy
Equivalent dose range 23–44 Gy
Chromosome aberration analysis (routinely stained metaphase plates)
Number of analyzed metaphase 
plates
2520 2550 2580
Aberrant metaphases 0.32 ± 0.05 1.80 ± 0.26* 2.69 ± 0.23*
Total number of aberrations 0.32 ± 0.15 2.00 ± 0.31* 3.01 ± 0.35*
Chromosome-type aberrations 0.15 ± 0.08 1.89 ± 0.26* 2.86 ± 0.29*
Paired fragments 0.08 ± 0.08 1.33 ± 0.28* 1.71 ± 0.23*
Ring chromosomes 0 0.03 ± 0.03 0.33 ± 0.19
Dicentric chromosomes 0 0.15 ± 0.08 0.15 ± 0.08
Atypical monocentrics 0 0 0.26 ± 0.07*
Double-minute chromosomes 0.07 ± 0.05 0.38 ± 0.20 0.40 ± 0.15
Chromatid-type aberrations 0.17± 0.07 0.11 ± 0.05 0.11 ± 0.06
Chromatid breaks 0.13 ± 0.07 0 0.07 ± 0.05
Isochromatid breaks 0.04 ± 0.04 0.11 ± 0.05 0.07 ± 0.05
Micronucleus test (using pancentromeric DNA-probe)
Total number of micronuclei 0.72 ± 0.05 1.28 ± 0.08* 1.87 ± 0.26*
Centromere-negative micronuclei 0.43 ± 0.56 0.97 ± 0.07 1.32 ± 0.19*
Centromere-positive micronuclei 0.29 ± 0.03 0.31 ± 0.04 0.55 ± 0.10
Nucleoplasmatic bridges 0 0.07 ± 0.03 0.10 ± 0.04
Notes: *statistically significant differences in comparison with level before 
treatment, P < 0.05
On the contrary to the frequency of centromere-
negative micronuclei, the level of centromere-positive 
micronuclei increased insignificantly after the neutron 
therapy (Table 1, 2). Centromere-positive micronuclei 
contain whole chromatid/chromosome(s) or centric 
chromosome fragments and they are produced as a re-
sult of indirect radiation effects expressed less mark-
edly after exposure to high-LET radiation (including 
neutrons). Therefore, significant increase of the levels 
of acentric fragments, centromere-negative micronu-
clei and insignificant increase of centromere-positive 
micronuclei are in agreement with the nature of fast 
neutrons. Regarding to the importance of these chro-
mosomal malformations for the cell fate, loss of chro-
mosomal fragments or whole chromosome usually 
leads to reduced viability of cells and decreased risk 
of malignant transformation.
Translocations are two-hit chromosome aberra-
tions and could be detected by the analysis of routinely 
stained metaphase plates as a dicentric chromosome 
or monocentric chromosome with atypical appear-
ance (atypical monocentrics). Misrepair of radiation-
induced damage in the peripheral blood lymphocytes 
of cancer patients in our study was observed as sig-
nificant increase of atypical monocentrics at the end 
of neutron therapy in both groups (Table 1, 2). Also, 
there was insignificant increase of dicentric chromo-
somes and corresponding nucleoplasmic bridges 
during the radiotherapy. Cells with atypical monocen-
trics are viable and a number of specific chromosome 
translocations are known to be a cause of leukemia 
[19]. Increase of stable translocation level in the lym-
phocytes of cancer patients during neutron therapy 
could possibly be a risk factor of radiation-induced 
secondary cancer.
Thus, in our study for the first time we have ob-
served cytogenetic effects of fast neutron therapy 
in lymphocytes of patients with parotid salivary gland 
tumors and relapse of breast cancer. It was shown 
that total increase of cytogenetic damages dur-
ing the treatment course is mainly due to formation 
of chromosome-type aberrations. A positive dynamics 
of the formation of radiation-induced chromosomal 
damage in the course of neutron therapy was observed 
in lymphocytes of cancer patients in both groups. Such 
bioindication of cytogenetic abnormalities are believed 
to be an important tool to assess the level of damage 
in irradiated tissues and could be used with the aim 
of optimization and individualization of the treatment.
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